AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02205801 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Superficial Cervical Plexus Block
Description: 0.25% Marcaine is injected lateral to the sternocleidomastoid bilaterally (10mL on each side) after induction of anesthesia and prior to incision and scheduled thyroidectomy or parathyroidectomy.
Study NCT02205801 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Superficial Cervical Plexus Block
Description: 0.25% Marcaine is injected lateral to the sternocleidomastoid bilaterally (10mL on each side) after induction of anesthesia and prior to incision and scheduled thyroidectomy or parathyroidectomy.
Study NCT02205801 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local Wound Infiltration
Description: 0.50% Marcaine is injected at the site of incision (10mL) after induction of anesthesia and prior to incision and scheduled thyroidectomy or parathyroidectomy.
Study NCT02205801 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Local Wound Infiltration
Description: 0.50% Marcaine is injected at the site of incision (10mL) after induction of anesthesia and prior to incision and scheduled thyroidectomy or parathyroidectomy.
Study NCT02205801 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Study NCT02205801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marcaine
Study NCT00256854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole CR 2 mg Placebo
Description: Ropinirole CR placebo Tablets are presented as 7 mm round, bi-convex, white film coated tablets, de-bossed with 'GS' on both faces, containing matching placebo tablets of 2 mg.
Study NCT00256854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole CR 3 mg Placebo
Description: Ropinirole CR placebo Tablets are presented as 7 mm round, bi-convex, white film coated tablets, de-bossed with 'GS' on both faces, containing matching placebo tablets of 3 mg.
Study NCT03761134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sulfonylurea
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT03761134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulfonylurea
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT04596826 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dronabinol 5 MG
Description: oral administration
Study NCT04596826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol 5 MG
Description: oral administration
Study NCT02175082 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cycling at Forced rate
Study NCT02175082 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cycling at self-selected rate
Study NCT04596826 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dronabinol 10 MG
Description: oral administration
Study NCT02556073 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone action
Description: Smartphone applications (Apps) can provides a platform not only to share health information at the point-of-living, including health assessments, personalized health plans, but also to remind the patients' medication adherence regularly. With the application of modern smartphone-based asthma self management deserves further investigation to improve asthma control.
Study NCT02556073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: fluticasone/salmeterol 125/25 ug/puff, 2 puff bid plus salmeterol as-needed
Study NCT02556073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: usual care
Description: fluticasone/salmeterol 125/25 ug/puff, 2 puff bid plus salmeterol as-needed
Study NCT04596826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol 10 MG
Description: oral administration
Study NCT04596826 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration
Study NCT04596826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral administration
Study NCT01849900 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Knowing your body
Description: Women will receive the Knowing your body kit. The kit contains: 6 ovulation test strips, a 12 month menstrual log sheet/calendar, and a thermometer to help women determine their body temperature; and educational materials that contain information on female body parts involved in pregnancy, hormones and the menstrual cycle, how birth control works, body temperature changes, characteristics of cervical fluid, and adapting to pregnancy during the first trimester. Participants will receive a total of 10 visits. During the first visit, the nursing student/community health workers team will review the intervention kit and continue to discuss topics related to women's health during subsequent visits.
Study NCT01849900 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Healthy Lifestyle
Description: Women will receive educational materials on healthy lifestyle such as maintaining good nutrition and the importance of folic acid for women of childbearing age during the first visit. Participants will receive a total of 10 visits. The nursing student/community health workers team will continue to discuss topics related to promoting healthy lifestyle during subsequent visits.
Study NCT01480440 — intervention group
Intervention type: DEVICE
Intervention: Trabecular Metal Reverse Shoulder System
Description: Trabecular Metal Reverse Shoulder System used in primary or revision total shoulder arthroplasty
Study NCT02584218 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-invasive resin based caries sealing
Description: The dentists use resin based sealants of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Pediatric Dentistry and Orthodontics, Federal University of Rio de Janeiro, Brazil
Study NCT02584218 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Invasive resin based restoration
Description: The dentists use preparation design and resin composites of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Pediatric Dentistry and Orthodontics, Federal University of Rio de Janeiro, Brazil
Study NCT00527514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Tablets
Study NCT00527514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil plus amlodipine
Description: Tablets
Study NCT00556764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [123I] IBVM and SPECT imaging
Description: Subjects will be injected with up to 4 mCi of 123-I IBVM followed by SPECT imaging.
Study NCT00556764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subjects will undergo the 123-I IBVM imaging visit
Description: Subjects will be injected with a bolus of up to 4 mCi of 123-I IBVM followed by serial SPECT imaging.
Study NCT03510377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquatic physical intervention
Description: For structured aquatic physical intervention group, the Ai-Chi method was selected. Ai-Chi is a simple aquatic exercise and relaxation method that uses a combination of deep breathing and slow movements of the arms, legs and torso in continual flowing patterns. The Ai-Chi intervention will occur in an hydrotherapy pool (34C).
Study NCT03510377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: On-land physical intervention
Description: For controlled comparison of the structured physical intervention group the Tai-Chi method was selected (the same movements as the Ai-Chi). The Tai-Chi intervention will occur in a room.
Study NCT03510377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non physical intervention
Description: The people who will be part of the non physical intervention will practice guided imagery of the Ai-Chi method. The guided imagery intervention will occur in a room.
Study NCT00631098 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: venous cannulation
Description: External jugular and cubital vein cannulation
Study NCT03928678 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: enhanced recovery after surgery program in colorectal cancer surgery
Description: to determine the feasibility of implementation of the ERAS protocol in our institute and its impact on hospital length of stay and outcome of surgery.
Study NCT03928678 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: enhanced recovery after surgery program in colorectal cancer surgery
Description: to determine the feasibility of implementation of the ERAS protocol in our institute and its impact on hospital length of stay and outcome of surgery.
Study NCT04761341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUTROF TOTAL
Description: 1 per day over a course of 3 months
Study NCT04761341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NUTROF TOTAL
Description: 1 per day over a course of 3 months
Study NCT02161185 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: USL261
Description: 5 mg, intranasal dose for seizure cluster, may repeat as indicated by protocol
Study NCT03393702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: 1. Patients in this arm of the study receive identical capsules, containing 15 mg/kg of oral gabapentin.~2. Patients after surgery receive identical capsules, containing 7,5 mg/kg of oral gabapentin 2 times per day.
Study NCT02874079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample and cotton skin swabs
Study NCT02874079 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample and cotton skin swabs
Study NCT04744233 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Orange juice
Description: Subjects were enrolled to consume 500 mL of orange juice/day during three consecutive 14 days periods separated by 1 - 1.5 month washouts. The orange juices assayed were: freshly squeezed (FS), commercially available low pasteurized juice (LP) and juices treated by high-pressure processing (HPP) and by pulsed electric fields (PEF). All participants consumed the LP and the HPP orange juices. Six subjects consumed PEF-orange juice and other six consumed the FS-orange juice.
Study NCT01728662 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ELVR Procedure
Description: Lung Volume Reduction Procedure
Study NCT02230696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray
Description: 137 micro-grams Azelastine Hydrochloride, 50 micro-grams Fluticasone Propionate
Study NCT02230696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray
Description: 137 micro-grams Azelastine Hydrochloride, 50 micro-grams Fluticasone Propionate
Study NCT02230696 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Description: Placebo nasal spray
Study NCT00890084 — intervention group
Intervention type: DRUG
Intervention: Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ)
Description: Telmisartan 40mg or 80mg +/- HCTZ 12.5mg or 25mg
Study NCT03788408 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Psychotherapy and case management for refugee trauma
Description: CVT's approach emphasized active interdisciplinary coordination and a relational focus anchored in cultural humilityX to address survivors' priorities, empower survivors as the primary architects of their healing, and work alongside each survivor to co-construct meaning and behavioral change.
Study NCT03393702 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1. Patients in this arm of the study receive identical placebo capsules 1 hour before surgery.~2. Patients after surgery receive identical placebo capsules 2 times per day.
Study NCT04281433 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activa Bioactive
Description: Before cavity preparation and restoration, masticatory muscles activity will be evaluated by using electromyography. An electromyography detects the electrical potential generated by muscle cells. A total of 40 posterior teeth will be selected for this study and grouped into 2 main groups (20 for each group)) according to presence of caries in one or both side in patient (unilateral or bilateral). Split mouth technique will be used. The affected teeth will be treated by removing the caries and restored tooth with bulk fill composite material, after restoring the affected teeth. Masticatory muscles activity will be evaluated by using electromyography to detect any changes in masticatory muscles activity before and after restoration.
Study NCT03012061 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a white powder to be administered using ELLIPTA DPI which hold two individual blister strips, both of which contains lactose monohydrate blended with magnesium stearate.
Study NCT03012061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC
Description: UMEC is a white powder to be administered using ELLIPTA DPI which hold two individual blister strips, one of which contains GSK573719 blended with lactose blended with magnesium stearate and another one contains lactose monohydrate blended with magnesium stearate.
Study NCT03012061 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone Furoate
Description: FF is a white powder to be administered using ELLIPTA DPI which hold two individual blister strips, one of which contains GW685698 blended with lactose monohydrate and another one contains lactose monohydrate with magnesium stearate.
Study NCT03012061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate
Description: FF is a white powder to be administered using ELLIPTA DPI which hold two individual blister strips, one of which contains GW685698 blended with lactose monohydrate and another one contains lactose monohydrate with magnesium stearate.
Study NCT03012061 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albuterol/salbutamol
Description: Albuterol/salbutamol is to be administered via metered-dose inhaler as a rescue drug on need basis throughout the study.
Study NCT03012061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/salbutamol
Description: Albuterol/salbutamol is to be administered via metered-dose inhaler as a rescue drug on need basis throughout the study.
Study NCT03587298 — intervention group
Intervention type: PROCEDURE
Intervention: Real-Time (Supersonic)- 2D shear wave elastography (rt-SWE)
Description: The SWE is carried out intercostally. If possible, the patient should hold the breath for 5-10 seconds. So-called colour charts are used, which indicate the derived liver stiffness in colour-coded form. In addition to the visual assessment of these colour charts, the quantitative ROI-based measurement of the SWE in kPa is performed in the hardest appearing areas. The measurement is performed at 5 different sites of the liver parenchyma and all SWE values are recorded.
Study NCT03788408 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Psychotherapy and case management for refugee trauma
Description: CVT's approach emphasized active interdisciplinary coordination and a relational focus anchored in cultural humilityX to address survivors' priorities, empower survivors as the primary architects of their healing, and work alongside each survivor to co-construct meaning and behavioral change.
Study NCT00619567 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartbrain
Description: The initial session will be set for 10 minutes, with weekly increases (of 10 minutes) to a maximum of 30 minutes per day, 7 days a week. Each subject will be trained using the same modules of the Smartbrain protocol, with an emphasis on speed of information processing.
Study NCT02206308 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chimeric anti-CD20 monoclonal antibody
Study NCT03859401 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EnMPC (Ensemble Model Predictive Control) AP Controller
Description: This AP controller has the ability to anticipate exercise activity by use of trends seen during the Data Collection Period.
Study NCT03859401 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rMPC (Naïve Model Predictive Control) AP Controller
Description: This AP controller does not have the ability to anticipate exercise activity.
Study NCT00510458 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: LFIT™ Femoral Heads With X3® Insert
Description: LFIT™ Anatomic CoCr Femoral Heads With X3® Polyethylene Insert in total hip replacement
Study NCT03668262 — intervention group
Intervention type: DRUG
Intervention: Cis-atracurium
Description: Different concentration of cis-atracurium
Study NCT01700075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Lipidlowering: Atorvastatin (Liprimar) - 40mg per day. Antihypertensive: Diroton (Lisinopril, Gedeon Richter Ltd) - 10mg twice per day and Ditiazem (calcium bloker from the benthodiazepines, Lannacher, Austria) - 90mg per day.~Antihyperglycemic drugs: biguanides Metformin - 0.5 g two or tree times per day, or Exenatide - 5-10 µg per day.~Anti-inflammatory: TromboACC (acetylsalicylate acid) up to 2 g per day and/or Clopidogrel (thienopyridine class antiplatelet agent) - 75mg per day.
Study NCT01700075 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Weight loss treatment
Description: Weight loss treatment by administering a healthy very low-calorie, low-fat vegetables and salt diet and includes an adjustment and modify eating behavior and increased physical activity.
Study NCT01154296 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RESPECT-2 Counseling
Description: Specifically designed for use with the rapid HIV test, involves a brief (approximately 20-40 minute) counseling session which includes an orientation to the rapid testing procedure, an explanation of the testing window period, routes of HIV transmission and the meaning of test results, a personalized exploration of risk, the creation of a risk-reduction plan, identification of sources for support and referrals, and HIV test results.
Study NCT01545778 — intervention group
Intervention type: DRUG
Intervention: Tapentadol IR
Description: Opioid naive patients exposed to tapentadol IR from July 2009 to December 2010.
Study NCT03970148 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nd: YAG laser
Description: Before treatment an optical coherence tomography (OCT) scan of the macula is performed to monitor possible macular oedema. After application of anesthetic and midriatics drops, the patient is positioned on the chin and forhead support (ND: YAG laser). Then, a contact lens (panfundoscope) is filled with methylcellulose and placed on the cornea. The laser is focused on the opacity that is to be treated and the first laser stamp of an initial power of 3 mJ is applied. The measured direct effect will guide in further adjustment of the laser beam power to achieve the desired effect. After treatment, a single drop of corticosteroid is applied to the patient and an ocular patch is applied. On follow up days an OCT scan of the macula is performed to monitor possible side effects.
Study NCT01171703 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: femoral-popliteal bypass
Description: Before operation, take aspirin 100mg every day. Groin and suprageniculate incision, PTFE graft with end to side anastomoses.
Study NCT02874651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Patients will take oral apatinib. The initial dose is 500 mg once daily. 28 days as one cycle. After 1 cycle, the dose will be escalated to 750 mg once daily in patients with good tolerance. Dose interruption or reduction is permitted in case of adverse events per protocol.
Study NCT01545778 — intervention group
Intervention type: DRUG
Intervention: Oxycodone IR
Description: Opioid naive patients exposed to Oxycodone IR from July 2009 to December 2010.
Study NCT00915460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (Avonex)
Description: dosage and frequency as per Biogen Idec protocol
Study NCT02874651 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will take oral placebo. The initial dose is 500 mg once daily. 28 days as one cycle. After 1 cycle, the dose will be escalated to 750 mg once daily in patients with good tolerance. Dose interruption or reduction is permitted in case of adverse events per protocol.
Study NCT01534884 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: 1000 mg by intravenous (IV) infusion. Each patient may receive 2 courses of treatment.
Study NCT01257659 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: STARR rectocele repair
Description: The STARR transanal stapling system is used to repair a rectocele.
Study NCT01257659 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Elevate mesh rectocele repair
Description: A posterior Elevate mesh is placed transvaginally to repair a rectocele.
Study NCT04803578 — intervention group
Intervention type: OTHER
Intervention: Conventional physiotherapy
Description: The subjects will receive rehabilitation according to the guidelines on the management of subjects after knee or hip arthroplasty, recovery of joint Range of Motion, recovery of lower limb strength, education to the crutches management, and stairs climbing and descending
Study NCT01979731 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Job rotation
Description: The intervention group will perform rotation function, switching between tasks with low, moderate and high ergonomic risk and different requests for ergonomic body region added to ergonomic guidelines.